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Exacerbation of asthmaAbstract Background: Receptor of advanced glycation end products (RAGE) is a new marker of
inflammation in different inflammatory disorders. Bronchial asthma as an inflammatory disease is
associated with increased levels of many markers of inflammation which are used to evaluate the
severity of childhood asthma, and may be the targets of new therapeutic options aiming at improv-
ing the management of such diseases.
Aim: To evaluate serum levels of RAGE in acute asthma exacerbation in children, and also to
correlate their levels with peak expiratory flow rate (PEFR) and number of exacerbations during the
last 6 months.
Methods: One hundred asthmatic children, aged 6–12 years, with acute exacerbation were eval-
uated during their visit to ER unit for serum RAGE (measured by ELISA) and PEFR before receiv-
ing any treatment. They were 53 males and 47 females. Fifty subjects were taken as controls for
serum RAGE.
Results: Serum RAGE was significantly higher in asthmatic children compared to control group.
It was higher in asthmatic children who had poor response to initial therapy at emergency room.
Serum RAGE showed significant negative correlation with PEFR and significant positive correla-
tion with a number of asthma exacerbations during the last 6 months.
Conclusion: Serum RAGE is elevated during acute asthma exacerbation in children. High levels
above 1733.5 pg/mL can expect poor response to initial therapy at emergency room and need for
hospitalization with sensitivity and specificity and a specificity of 90.5% and 83.35% respectively.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest
Diseases and Tuberculosis. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Bronchial asthma is by far the most common chronic disease
of childhood and it is considered to be the leading cause of
childhood morbidity caused by chronic diseases leading torculosis.
Table 1 Demographic data and peak expiratory flow rate
(PEFR) of the studied subjects.
Control
(No = 50)
Asthmatic
(No = 100)
t p
Age in years 8.1 ± 1.8 8.2 ± 2.1 1.1 0.28
BMI in kg/m2 20.8 ± 3.8 21.3 ± 4.2 1.2 0.25
Male/female 24/26 53/47 v2 = 1.6 0.48
Age at time of
diagnosis
– 3.2 ± 1.6
Associated nasal
allergy
– 55%
Immediate family
history of asthma
6% 58%
Blood eosinophils % 2.1 ± 0.3 7.1 ± 2.4 5.6 0.009*
PEFR
(% of predicted)
93.1 ± 8.3 48.2 ± 6.4 6.3 0.008*
* Significant.
16 A.S. Bediwy et al.absence from school, emergency department (ER) visits and
hospitalization [1].
Asthma exacerbation is a well known factor that can
increase the risk of asthma mortality [2].
As an inflammatory disease, pediatric asthma was associ-
ated with high levels of many inflammatory markers [3,4].
The receptor for advanced glycation end products (RAGE),
a member of the immunoglobulin superfamily of cell surface
molecules, is involved in the signal transduction from patho-
gen substrates to cell activation during the onset and continu-
ation of inflammation [5].
Its involvement in inflammation has been suggested, that
RAGE is upregulated in all inflammatory lesions studied,
including rheumatoid arthritis, inflammatory kidney disease,
arteriosclerosis, inflammatory bowel disease and others [6].
RAGE was first identified in lung tissue, it is located on the
basolateral membranes of alveolar epithelial type I cells but
RAGE mRNA has also been found in alveolar epithelial type
II cells [7].
The aim of this study was to evaluate the serum levels of
RAGE in asthmatic children during exacerbation compared
to control subjects and find a relationship between these levels
and outcome of asthma exacerbation.
Subjects and methods
This study was carried out in Pediatric Department, Tanta
University Hospital, Egypt between June 2013 and December
2013.
We examined 100 children attending the emergency room
of Pediatric Department with asthma exacerbations. A control
group consisting of fifty age and sex matched children was
included in our study.
Written informed consents were obtained from parents of
all children.
Inclusion criteria of patients:
 Age was ranging from 6 to 12 years.
 Diagnosis of bronchial asthma according to GINA guide-
line and National Asthma Education and Prevention Pro-
gram, 2007.
 Patients were coming to emergency room due to exacerba-
tion of their asthma.
Exclusion criteria:
 Patients with other pulmonary disorders as bronchiectasis
and cystic fibrosis.
 Children below 6 years or above 12 years of age.
 Children of control group had no chest troubles and nega-
tive history of steroid use in last 6 months. All of them had
negative personal and family history of wheezy chest,
asthma or nebulizer use before.
All subjects had detailed history taking, and thorough clin-
ical examination. Peak expiratory flow rate (PEFR) was mea-
sured in all of them.
Blood samples were taken from all patients in the ER unit
during acute asthma exacerbation before any rescue medica-
tion was given to them.Patients were given standard treatment of asthma exacerba-
tion and then re-assessed after 1 h for response to initial ther-
apy. Children with good response are who did not need
admission and with no return of exacerbation for 1 week. Chil-
dren with poor response are who needed admission to the hos-
pital or returned back within 1 week with another
exacerbation.
Determination of RAGE serum level: estimation of RAGE
in the serum pg/mL by enzyme immunoassay supplied by Ray-
Biotech, Inc.
The RayBio Human RAGE ELISA (Enzyme-Linked
Immunosorbent Assay) kit is an in vitro enzyme-linked
immunosorbent assay for the quantitative measurement of
human RAGE in serum. This assay employs an antibody
specific for human RAGE coated on a 96-well plate. Standards
and samples are pipetted into the wells and RAGE present in a
sample is bound to the wells by the immobilized antibody. The
wells are washed and biotinylated anti-human RAGE
antibody is added. After washing away unbound biotinylated
antibody, HRP-conjugated streptavidin is pipetted to the
wells. The wells are again washed, a TMB substrate solution
is added to the wells and color develops in proportion to the
amount of RAGE bound. The Stop Solution changes the color
from blue to yellow, and the intensity of the color is measured
at 450 nm.
Results
One hundred children with asthma exacerbation and fifty con-
trol children were included in our study. The demographic
data and peak expiratory flow rate (PEFR) of both patients
and control are demonstrated in Table 1.
Mean RAGE serum levels were 1770.1 ± 423.3 pg/mL in
children with asthma exacerbation, and 745 ± 224.6 pg/mL
in control children (Table 2).
Serum RAGE levels showed significant negative correlation
with PEFR and significant positive correlation with a number
of asthma exacerbations during the last 6 months before inclu-
sion in the study (Table 3).
After initial therapy in the emergency room, 55 patients
showed good response and 45 patients showed poor response.
Table 2 Comparison between cases and control according to
their sRAGE.
RAGE
Patients Control
Range 855–2534 121–946
Mean 1770.1 745
±SD 423.3 224.6
t. test 48.225
p. value 0.001*
* Significant.
Table 3 Correlation between serum RAGE and both PEFR
and the number of asthma exacerbations during the last
6 months.
Correlation between sRAGE and: R p
PEFR 0.9 0.011*
No of exacerbations during the last 6 months 0.992 0.013*
* Significant.
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Figure 1 ROC curve showing serum RAGE to differentiate
between good and poor responder to initial ER therapy with
sensitivity and specificity 90.5% and a specificity of 83.35%
respectively at an optimal cutoff value of 1733.5 pg/mL.
RAGE in childhood asthma exacerbation 17On reviewing the sRAGE levels of both of them it was noticed
that it was significantly higher in those with poor response
than those with good response (1920 ± 432 versus 1540
± 390 pg/mL respectively with t= 6.5 and p= 0.007).
Receiver-operating characteristic (ROC) curve analysis
showed that serum RAGE level had a sensitivity of 90.5%
(95% confidence interval (CI): 69.27–98.81%) and a specificity
of 83.35% (95% CI: 62.6–95.3%) for differentiating between
good and poor response to initial therapy at emergency room
at an optimal cutoff value of 1733.5 pg/mL. The likelihood
ratio positive (LR+) was 5.412, and the likelihood ratio neg-
ative (LR) was 0.114. The area under the ROC curve
(AUC) was 0.9444 (Fig. 1).
Discussion
Historically, the receptor for advanced glycation end products
(RAGE) was thought to exclusively play an important role
under hyperglycemic conditions. However, more and more evi-
dence suggests that RAGE in fact is an inflammation perpetu-
ating multi-ligand receptor and participates actively in various
vascular and inflammatory diseases even in normoglycemic
conditions [8].
Under pathologic conditions, RAGE is up-regulated in
blood vessels, neurons, and transformed epithelia and is
involved in several chronic diseases, such as rheumatoid arthri-
tis, diabetes, inflammatory kidney disease, arteriosclerosis,
inflammatory bowel disease, neurodegenerative disorders,
and wound-healing disorders [9].
Most tissues display a relatively low expression of RAGE in
their normal physiological state. However, lung has been iden-
tified as an exception; as RAGE is constitutively expressed at a
high basal level in pulmonary tissue, localized primarily in
alveolar type I (ATI) pneumocytes [10]. Alterations in RAGE
levels and RAGE–ligand interaction have been suggested to
play a relevant role in the pathogenesis of several pulmonary
diseases. Acute lung injury (ALI) and acute respiratory distresssyndrome (ARDS), a more severe manifestation, are syn-
dromes of acute respiratory failure, hallmarked by hypoxemia,
disruption of alveolar fluid clearance (AFC), deterioration of
the alveolar-capillary barrier, and, most importantly, damage
to ATI pneumocytes [11,12].
Increased levels of RAGE were demonstrated in bron-
choalveolar lavage fluid (BALF) in various direct models of
lung injury induced separately by intratracheal instillation of
hydrochloric acid, lipopolysaccharide (LPS), or Escherichia
coli as well as exposure to hyperoxia [13].
In the present study, we evaluated the serum level of RAGE
in asthmatic children during asthma exacerbation before
receiving any rescue treatment in ER in 100 asthmatic children
and 50 healthy controls.
Up to our knowledge, there are no published papers evalu-
ating serum levels of RAGE in asthmatic children during exac-
erbation in Middle East, reflecting the importance of this
study.
We found the mean serum levels of RAGE were higher in
asthmatic patients during exacerbation compared to control
group, indicating that RAGE may be considered as an inflam-
matory marker sharing in the pathogenesis of childhood
asthma, and it may be the target of new therapeutic interven-
tions. Moreover, we found that serum RAGE was even higher
in children who showed poor response to initial therapy at the
emergency room reflecting its importance in evaluating drug
response in asthmatic children. Serum RAGE was able to dif-
ferentiate between good and poor responder to initial ER ther-
apy with sensitivity and specificity 90.5% and a specificity of
83.35% respectively at an optimal cutoff value of 1733.5
pg/mL.
Also, sRAGE showed a significant negative correlation
with PEFR and significant positive correlation with the num-
ber of asthma exacerbations during the last 6 months.
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[14] who found that blood level of RAGE was found to be
higher in asthmatic subjects in comparison to COPD patients
and control group. Another experimental study [15] has shown
that RAGE is more expressed in asthmatic airways and giving
RAGE inhibitors markedly decreased inflammation in animal
model of asthma. El-Seify et al. [16] found that Serum level of
sRAGE correlated with severity of bronchial asthma clinically
and functionally.
More multicenter studies are needed on larger number of
asthmatic children and to detect also the effect of anti-
asthma medications on serum RAGE.
Conclusion
Serum RAGE is elevated during acute childhood asthma exac-
erbation in comparison to control subjects. High levels above
1733.5 pg/mL can expect poor response to initial therapy at
emergency room and need for hospitalization with sensitivity
and specificity 90.5% and a specificity of 83.35%.
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